ReviewThoracic cancer2022
Prognostic factors and genetic markers in thymic epithelial tumors: A narrative review.
Review in Thoracic cancer, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
11 citing papers in PubMed, 12 citations in OpenAlex.
- Machine Learning-Based Prediction of Masaoka-Koga Stage and WHO Histological Risk Group in Thymic Epithelial Tumors Using Biomarker Combinations.Diagnostics (Basel, Switzerland) · 2026Article
- Long-Term Outcomes of Surgical Resection for Thymic Epithelial Tumour With Intrathoracic Dissemination.Interdisciplinary cardiovascular and thoracic surgery · 2026Article
- Prognostic and predictive biomarkers in thymic epithelial tumors: beyond traditional staging: a narrative review.Mediastinum (Hong Kong, China) · 2026Review
- HER2 expression andMediastinum (Hong Kong, China) · 2026Review
- Long-term survival after superior vena cava resection and reconstruction for locally advanced epithelial thymic tumors invading superior vena cava.JTCVS open · 2025Article
- Machine learning-based radiomics analysis in enhancing CT for predicting pathological subtypes and WHO staging of thymic epithelial tumors: a multicenter study.American journal of cancer research · 2025Article
- Cell Culture Models for Translational Research on Thymomas and Thymic Carcinomas: Current Status and Future Perspectives.Cancers · 2024Review
- Surgical treatment of thymic epithelial tumors: a narrative review.Mediastinum (Hong Kong, China) · 2024Review
- Prognostic factors in patients with thymoma who underwent surgery.World journal of surgical oncology · 2023Article
- Epigenetics of Thymic Epithelial Tumors.Cancers · 2023Review
- Prognostic factors and genetic markers in thymic epithelial tumors: A narrative review.Thoracic cancer · 2022Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Thymic epithelial tumors (TET) are a group of rare neoplasms of the anterior mediastinum comprising thymomas and thymic carcinomas. The carcinogenesis of TET is mostly unknown. Many studies, mostly retrospective case series, have tried to establish prognostic factors in TET. TET is a very heterogeneous group of tumors with many subtypes for which diagnosis and treatment remains a very challenging task. Despite the disparities among retrospective studies, there are some prognostic factors that are more pertinent such as the completeness of resection, TNM stage and the Masaoka-Koga classification. On the other hand, the identification of different genetic pathways that result in the pathogenesis of TET represents a fascinating field of study that could possibly lead to the development of new targeted therapies. The aim of this review is to discuss the different prognostic factors and genetic markers of TET. The meticulous use of national and international databases could provide sufficient number of patients in order to draw more valid conclusions.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.